Series A · Biotech · Gothenburg, Sweden · Founded 2019 · 10–15 employees
Atley Solutions is the global leader in commercial products and services for astatine-211 (At-211) radiopharmaceuticals, specializing in targeted alpha therapy for cancer treatment. The company has developed the Atley C100, the world's first commercial manufacturing system purpose-built for At-211 radiopharmaceuticals, addressing key manufacturing challenges in this promising oncology field. In June 2025, they secured €5 million in Series A funding led by Fåhraeus Startup & Growth, with continued support from existing investors including Chalmers Ventures. The company was founded in 2019 by Milton Lönnroth, Emma Aneheim, and Sture Lindegren, spinning out from pioneering research at the University of Gothenburg's Targeted Alpha Therapy Group.
No open roles listed right now.